Literature DB >> 12721766

Current therapies in Hodgkin's disease.

K E Kogel1, J W Sweetenham.   

Abstract

Advances in the treatment of Hodgkin's disease (HD) have resulted in cure rates of greater than 80%. This remarkable achievement has occurred in the past 50 years secondary to improvements in combination chemotherapy and radiotherapy. Over the last several decades, with the increase in long-term survivors of HD, it has become evident that cure is not the only issue, and late side-effects of treatment, including secondary malignancies and impaired fertility, are of major concern as well. As a result, attempts to improve response and survival rates by intensifying therapy must be countered against the potential for long-term toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721766     DOI: 10.1007/s00259-003-1156-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  49 in total

1.  Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease.

Authors:  A R Yuen; S A Rosenberg; R T Hoppe; J D Halpern; S J Horning
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

2.  Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease.

Authors:  H M Vriesendorp; S M Quadri; C T Wyllie; J Lai; P E Borchardt; L Harris; R Wucher; E Askew; L Schweichler
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

3.  Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease.

Authors:  A Santoro; V Bonfante; G Bonadonna
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

4.  Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease.

Authors:  R Zittoun; A Audebert; B Hoerni; A Bernadou; M Krulik; J Rojouan; H Eghbali; H Merle-Béral; Y Parlier; J Diebold
Journal:  J Clin Oncol       Date:  1985-02       Impact factor: 44.544

5.  Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study.

Authors:  C J Fabian; C M Mansfield; S Dahlberg; S E Jones; T P Miller; E Van Slyck; P N Grozea; F S Morrison; C A Coltman; R I Fisher
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

Review 6.  Current strategies of antibody-based treatment in Hodgkin's disease.

Authors:  R Schnell; P Borchmann; H Schulz; A Engert
Journal:  Ann Oncol       Date:  2002       Impact factor: 32.976

7.  ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.

Authors:  T Chisesi; M Federico; A Levis; G Lambertenghi Deliliers; P G Gobbi; G Santini; S Luminari; M Brugiatelli Linfomi
Journal:  Ann Oncol       Date:  2002       Impact factor: 32.976

8.  Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study.

Authors:  G P Biti; G Cimino; C Cartoni; S M Magrini; A P Anselmo; R M Enrici; G P Bellesi; A Bosi; G Papa; D Giannarelli
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

9.  ChlVPP therapy for Hodgkin's disease: experience of 960 patients. The International ChlVPP Treatment Group.

Authors: 
Journal:  Ann Oncol       Date:  1995-02       Impact factor: 32.976

10.  Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital.

Authors:  T S Ganesan; P F Wrigley; P A Murray; A G Stansfeld; A J d'Ardenne; S Arnott; A Jones; W S Shand; J S Malpas; T A Lister
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

View more
  5 in total

Review 1.  Positron emission tomography in the management of lymphomas: a summary.

Authors:  M J O'Doherty; P J Hoskin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-12       Impact factor: 9.236

Review 2.  Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature.

Authors:  Catherine E Mosher; William H Redd; Christine M Rini; Jack E Burkhalter; Katherine N DuHamel
Journal:  Psychooncology       Date:  2009-02       Impact factor: 3.894

Review 3.  Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk.

Authors:  J G Franklin; M D Paus; A Pluetschow; L Specht
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

4.  Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease.

Authors:  Foad Azem; Nivin Samara; Tanya Cohen; Dalit Ben-Yosef; Beni Almog; Joseph B Lessing; Odeliya Goor; Ami Amit
Journal:  J Assist Reprod Genet       Date:  2008-11-18       Impact factor: 3.412

5.  Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.

Authors:  Catarina Policiano; Jessica Subirá; Alejandra Aguilar; Susana Monzó; Ignacio Iniesta; Jose María Rubio Rubio
Journal:  J Assist Reprod Genet       Date:  2020-06-02       Impact factor: 3.412

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.